Preoperative tyrosine kinase inhibitors risk bowel anastomotic healing of advanced primary and recurrent/ metastatic gastrointestinal stromal tumors Jin-Chiao.

Slides:



Advertisements
Similar presentations
Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Advertisements

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
GIST Research at Fox Chase Cancer Center Margaret von Mehren, MD.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Gastrointestinal Stromal Tumor
Major sites of GIST metastases:
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Surgical Management of Advanced GIST Following KIT- Directed Therapy Chandrajit P. Raut, Jayesh Desai, Jeffrey A. Morgan, Suzanne George, Matthew Posner,
Neoadjuvant Imatinib, Surgery and then ? Seattle 2007 Neoadjuvant Imatinib, Surgery and then ? Department of Surgery 1 and Medical Oncology 2 Netherlands.
Management of GIST Dr Kwan Ming Wa Tuen Mun Hospital.
Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup study.
Joint Hospital Surgical Grand Round (25 Jan 2014) Lok Hon Ting (Prince of Wales Hospital)
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Gastrointestinal Stromal Tumors Twelfth GRW Symposium Surgical Grand Rounds
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Adductor Compartment STS - Does method of treatment affect outcome? Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert.
11 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al.
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
“INTEGRAZIONE TRA TERAPIA CHIRURGICA E TERAPIA MEDICA” Camillo Porta, MD Medical Oncology I.R.C.C.S. San Matteo University Hospital Foundation, Pavia.
Jens Jakob 1 ; Anna Simeonova 2 ; Bernd Kasper 3 ; Ulrich Ronellenfitsch 1 ; Frederik Wenz 2 ; Peter Hohenberger 1 1 Department of Surgery, 2 Department.
Extra-Abdominal Fibromatosis : The Birmingham Experience
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
San Antonio Breast Cancer Symposium, December 8-12, 2015
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Salvage Nipple-Sparing Mastectomy and Immediate Breast Reconstruction after Previous Breast Conservation Therapy: Same Safety, Better Cosmesis Che-Hsiung.
Surgical Approaches to GIST in the Era of Targeted Therapy Kevin G. Billingsley, M.D. Hedinger Professsor of Surgery Chief, Division of Surgical Oncology.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Short-term outcome of neo-adjuvant chemotherapy
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Mechanical bowel preparation with oral antibiotics reduces surgical site infection and anastomotic leak rate following elective colorectal resections.
Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Metastatic/Recurrent Gastrointestinal Stromal Tumors (M/R-GIST): Does surgical resection improve survival?
Dr Monem Alshok Merjan Teaching Hospital GIT centre
Laparoscopic vs Open Colonic Surgery: Long Term Survival
Joensuu H et al. Proc ASCO 2011;Abstract LBA1.
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Barrios C et al. SABCS 2009;Abstract 46.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Surgical Approaches to GIST in the Era of Targeted Therapy
Adjuvant Radiation is Required for Gastric Cancer
The 8th edition American Joint Committee on gastric cancer pathological staging classification performs well in a population with high proportion of.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
Neoadjuvant Adjuvant Curative Palliative
ALLPPT.com _ Free PowerPoint Templates, Diagrams and Charts
Does Liver Regeneration Increase the Postoperative HCC Recurrence after Curative Resection ? Jin-Ho Lee, MD. Department of Surgery, Yonsei University.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Branford S et al. Proc ASH 2013;Abstract 254.
高雄榮民總醫院耳鼻喉頭頸部 林陞樵 林曜祥 康柏皇 張庭碩
Presentation data from US VICTORY Consortium
Presentation data from US VICTORY Consortium
Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.
Risk factors for postoperative infection after lower gastrointestinal surgery in patients with inflammatory bowel disease: Findings from a large epidemiological.
Surgical resection of metachronous liver metastases
Presentation transcript:

Preoperative tyrosine kinase inhibitors risk bowel anastomotic healing of advanced primary and recurrent/ metastatic gastrointestinal stromal tumors Jin-Chiao Lee1, Chun-Han Chen2, Tse-Ching Chen3, Chun-Yi Tsai1, Keng-Hao Liu1, Jun-Te Hsu1, Chun-Nan Yeh1, Ta-Sen Yeh1, Tsann-Long Hwang1, Yi-Yin Jan1, Min-Fu Chen1 Departments of Surgery,1 and Pathology,3 Chang Gung Memorial Hospital at LinKou, Chang Gung University Medical College, Taoyuan, Taiwan Departments of Surgery,2 Chang Gung Memorial Hospital at Chia-Yi, Taiwan

Background Surgery was the only effective treatment for gastrointestinal stromal tumor (GIST) before 2001 Dramatic improvement in GIST management was achieved with the use of tyrosine kinase inhibitors (TKI) For GIST, surgery was the only effective treatment before 2001 because of the limited response to chemotherapy and radiotherapy Until the use of tyrosine kinase inhibitors , including imatinib (IM), sunitinib (SU) and regorafenib, the outcome of GIST had dramatic improvement

Surgery after TKI Cytoreduction surgery in advanced GIST Recurrent GIST after adjuvant therapy Oncologic emergency during TKI treatment Resection after neoadjuvant TKI treatment Because of the wide-spread use of TKI, many patients underwent surgery after TKI treatment. There are four common surgical indications, including resection of recurrent GIST after adjuvant therapy, cytoreduction surgery in advanced GIST, Oncologic emergency during TKI treatment, such as bleeding, obstruction or perforation, and the last one is noeadjuvant TKI.

Postoperative complications Postoperative complication rate was high after use of TKI 58% after imatinib (DeMatteo R.P et al. Ann of Surg. 2007) 54% complications and 15.3% major complications after sunitinib (Raut C.P. et al. Ann Surg Oncol. 2010) (Yeh C.N. et al. Int J surg 2017) Despite the TKI and cytoreduction surgery gave patients better survival outcome, the postoperative complication rate was extremely high after use of TKI. Dr Dematteo reported the complications up to 58% after imatinib in 2007. and Dr Raut and Dr Yeh found 54% of the patients had complications and 15.3% of the patient had major complications after use of preoperative sunitinib. These reported complication rates were obviously higher than other elective surgery.

Aim Evaluate the effect of preoperative tyrosine kinase inhibitors on postoperative complications Our aim was to evaluate the effect of preoperative TKI on postoperative complications.

Patients and method

Patients Cohort From March 1991 to June 2017 Inclusion Criteria Patients who underwent surgery for pathologic proven GIST in CGMH – Linkou branch Exclusion Criteria Surgery for previous complications Patients without complete data Our patient cohort was from March 1991 ot June 2017. The inclusion criteria was the patient who underwent surgery for pathologic proved GIST in Linkou CGMH, and the surgery for previous complications or incomplete data were excluded from our study.

Method Patients were classified by use of preoperative TKI or not into 2 groups Postoperative complications were recorded according to the Clavien-Dindo classification We further classified the patients in to 2 group by use of pre-operative TKI or not. The postoperative complications was recorded according to Clavien-Dindo classification.

Results

Before Matching After Matching   Before Matching After Matching Factors Pre-OP TKI p value Yes (n=108) No (n=108) No (n=505) Age (years) <60 60 (55.6) 258 (51.1) 0.399 58 (53.7) 0.785 >60 48 (44.4) 247 (48.9) 50 (46.3) Sex 0.002 0.662 Male 72 (66.7) 253 (50.1) 75 (69.4) Female 36 (33.3) 252 (49.9) 33 (30.6) CCI 7 (6.5) 48 (9.5) 0.245 11 (10.2) 0.459 1-2 45 (41.7) 171 (33.9) 38 (35.2) >3 56 (51.9) 286 (56.6) 59 (54.6) Surgery with anastomosis <0.0001 0.561 Yes 71 (65.7) 461 (91.3) No 37 (34.3) 44 (8.7) Primary Site 0.018 0.676 Stomach 44 (40.7) 269 (53.3) 41 (38.0) Other 64 (59.3) 236 (46.7) 67 (62.0) Size 8.5 + 5.1 6.6 + 4.9 <0.001 8.5 + 5.3 0.976 Risk 0.300 None 3 (2.8) 57 (11.3) 6 (5.6) Very Low 3 (3.2) 94 (18.6) Low 21 (19.8) 85 (16.8) 12 (11.1) Medium 19 (18.6) 83 (16.4) 19 (17.6) High Unknown 3 (3.0) There were 613 patients who underwent surgery for GIST. 108 patients had preoperative use of TKI, we called them TKI group, and 505 patient had no use of TKI, we called them non-TKI group. We can see that there are several significant difference between two groups, including sex, surgery with anastomosis or not, primary site, size and risk. So we try to even out the bias between two groups. We did the propensity score matching, and there are 108 patients in each groups after matching. All the difference between two groups are even out. Then we check our primary outcome.

Post-operative complications   Before Matching After Matching Factors Pre-OP TKI p value P Yes (n=108) No (n=505) No (n=108) Post-OP complication <0.0001 Yes 37 (34.3) 35 (6.9) 11 (10.2) No 71 (65.7) 470 (93.1) 97 (89.8) Grade of post-OP complication 473 (93.1) 1-2 19 (17.6) 27 (5.3) 8 (7.4) 3-5 18 (16.7) 8 (1.6) 3 (2.8) Anastomosis related complications 0.032 13 (18.3) 13 (2.8) 5 (6.7) 58 (81.7) 448 (97.2) 70 (93.3) Our primary outcome was postoperative complications. The TKI groups had significant higher postoperative complications rate compared with non TKI group. The complications rate was 34.3% in TKI group and 6.9% in non-TKI group, p value was less than 0.0001. The anastomosis related complications was also significantly higher in TKI groups, with 18.3% versus 2.8% in nonTKI group. Then we did the propensity score matching to even out the demographic bias, and the difference of postoperative complications was still signicant after propensity score matching in both complications and anastomosis related complications.

Univariant and Multivariant analysis – major complications Factors Odds ratio 95% C.I. P value p value Age (years)   >60/<60 1.481 0.702-3.122 0.303 Sex Male/Female 1.093 0.520-2.296 0.815 CCI >3/<3 1.383 0.644-2.968 0.406 Pre-OP TKI Yes/No 7.482 3.344-16.739 <0.001 6.256 2.224-17.599 0.001 Repeat Surgery Yes/ No 5.573 2.611-11.891 2.234 0.959-5.205 0.062 Primary Site Stomach/Other 2.060 0.926-4.583 0.077 Size >10cm/<10cm 1.441 0.644-3.223 0.374 Risk High/None-Medium 3.361 1.509-7.490 0.003 1.470 0.539-4.010 0.452

Discussion

TKI impairs wound healing A number of currently approved TKIs are suspected or have been reported to impair wound healing There have been no formal clinical trials to evaluate the extent of the risk (Shah D.R et al. Drug Saf. 2014)

TKI impairs wound healing (Shah D.R et al. Drug Saf. 2014) Some of the TKIs were labelled to have the risk of impairing wound healing, and were suggested to be stopped before the elective surgery based on its half-life.

Imatinib impairs wound healing through PDGFR Fibroblast migration and proliferation Collagen Type I Biosynthesis Angiogenesis during wound healing (Rajkumar et al. AJP 2006) Dr Rajkumar in 2006 used animal studies and laboratory experiments to find that imatinib impairs fibroblast migration and proliferation, Collagen Type I biosynthesis and angiogenesis during wound healing. The picture showed the healing of punch wound on mice was obviously impaired after used of imatinib.

Pre-OP use of TKI increased postoperative complications Patient with pre-operative use of TKI had significantly higher postoperative complications compared to those without the use of TKI. 34.3% versus 6.9%, p < 0.001 34.3 % versus 10.2%, p < 0.001, after propensity score matching Anastomosis insufficiency 18.3% versus 2.8%, p < 0.001 18.3% versus 6.7%, p = 0.032, after propensity score matching Back to our clinical data, the preoperative use of TKI increased the rate of postoperative complications and anastomosis insufficiency, and the findings were significant even after propensity score matching.

Conclusion Preoperative use of TKI significantly increased the rate of postoperative complication and anastomosis insufficiency.

Conclusion Discontinuation of the TKI medication based on its half-life is suggested before elective surgery. The anastomosis of GI tract has a high risk of insufficiency after use of TKI, and thus requires a more meticulous technique and close postoperative monitoring.

Thanks for your attention!

TKI in adjuvant therapy Adjuvant imatinib following complete resection prolonged recurrence-free survival in patients with higher risk. Tumor size > 10 cm or high mitotic rate 2 years RFS improved from <50% to over 70% (DeMatteo R.P et al, Lancet 2009) The TKI can be used as adjuvant therapy. Adjuvant imatinib following complete resection was proved to prolong recurrence-free survival in patients with high risk GIST based on tumor size and mitotic count. 2 years RFS improved from <50% to over 70%

TKI in advanced GIST Improve median PFS and OS Pre-imatinib: both <12 months With imatinib: 18 months and 55 months 22 months and 69% at 2yrs 37.6 months and 71.0 months (Blanke CD et al. J Clin Oncol. 2008) (Verweij J et al. Lancet 2009) (Yeh C.N. et al. Transl. Oncol. 2011) For advanced GIST, including metastatic, locally advanced and unresectable disease, TKI can improve PFS and OS from both less than 1 year to 3 years and over 5 years.

Cytoreduction Surgery Benefit of cytoreduction surgery in metastatic GIST after imatinib has no been proved by randomized controlled trial. Patient whosed disease responds to imatinib benefit more from surgery than those with disease progression After use of TKI, cytoreduction surgery started to be use as part of the treatment for GIST. No phase III RCT can prove the benefit of cytoreduction surgery in advanced GIST. But if the patient had stable or partial response to TKI, they benefit more from cytoreduction surgery than those with progression disease.

Cytoreduction Surgery Surgery should be considered in Stable or responsive to TKI therapy Limited disease progression (Keung E.Z et al. Surg Clin N Am, 2017) So, cytoreduction surgery should be considered in patients with stable or partial response disease after TKI therapy, or at least limited progressed disease.

Propensity Score Matching Sex Size Risk Surgery with anastomosis Primary site And we did the propensity score matching to even out the demographic bias between two groups. We matched 5 factors, including sex, size, risk, surgery with anastomosis or not, and primary site of the GIST

Imatinib impairs wound healing through PDGFR (Rajkumar et al. AJP 2006) Staining of sections with Masson’s trichrome confirmed that granulation tissue in treated animals was poorly formed and relatively hypocellular (I, arrows) compared with control animals (H, arrows). Granulation tissue in control animals was characterized by the formation of small blood vessels (H, inset, arrowhead), which were not present in imatinib-treated wounds (I, inset, arrowhead).